<DOC>
	<DOC>NCT00888004</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.</brief_summary>
	<brief_title>Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patients with Parkinson's Disease Patients with Ldopa induced dyskinesia for at least 3 months Patients with Ldopa treatment for at least 3 years, stable for 1 month minimum History of severe allergy to food or drugs Very low or high body weight. Prior surgery for Parkinson's Disease Smokers Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Parkinson's</keyword>
	<keyword>L-dopa</keyword>
	<keyword>dyskinesia</keyword>
</DOC>